dHMN-5A

GARS1 | 2003

What Is dHMN-5A?

dHMN-5A is a type of CMT caused by autosomal dominant mutations in the GARS1 gene. This gene provides instructions for making glycyl-tRNA synthetase, an enzyme that attaches the amino acid glycine to its transfer RNA during protein synthesis. Mutations in the GARS1 gene disrupt this function, leading to impaired nerve signal transmission.

dHMN-5A is autosomal dominant, meaning that just one of the gene’s two copies needs a mutation to cause this subtype.

Clinical Features

The age of symptom onset in dHMN-5A is variable, ranging from childhood to early adulthood. Unlike many forms of CMT, dHMN-5A predominantly affects the upper limbs, with weakness and atrophy of the hand muscles often appearing early. The lower limbs typically become involved as the disease progresses. As a distal hereditary motor neuropathy, dHMN-5A predominantly affects the motor nerves, with sensation typically preserved. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

dHMN-5A symptoms may include:

  • Weakness in the hands, often as an early feature
  • Muscle atrophy, particularly of the hand muscles
  • Weakness in the feet and lower legs
  • Difficulty with fine motor skills and manual dexterity
  • Brisk reflexes
  • Foot deformities, including high arches
  • Foot drop
  • Additional symptoms not listed here

Disease Course

dHMN-5A shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
dHMN-5A

Classification
dHMN/HMN

Neuropathy Type
Axonal

Inheritance Pattern
autosomal dominant

Genetic Context

HGNC-Approved Gene Symbol
GARS1

Gene Full Name
Glycyl-tRNA Synthetase 1

HGNC Gene Alias(es)
GARS

Chromosome
7p14.3

Zygosity of Responsible Variant
Heterozygous

Variant Mechanism

Toxic Gain of Function (GoF)

Details

Mechanistic basis:
Neomorphic

Confidence:
Medium

Prediction:
The literature predicts a neomorphic toxic gain-of-function mechanism for dHMN-5A: dominant GARS1 mutations induce an aberrant open conformation that exposes a novel surface, causing aberrant binding to Nrp1 (antagonizing VEGF/Nrp1 signaling) and to Trk receptors and axonal mislocalization, rather than simple loss of aminoacylation. Null and loss-of-function GARS1 alleles do not cause the dominant phenotype and severity does not track residual activity, arguing against haploinsufficiency, so added wild-type is not predicted to rescue; a partial loss-of-aminoacylation contribution remains debated, holding confidence at medium.

Rationale:
Dominant GARS1 alleles acquire an aberrant open conformation with new Nrp1 and Trk binding on their own, with nulls unaffected and severity decoupled from enzyme activity, pointing to a neomorphic gain of function rather than disruption of wild-type GARS1. A partial loss-of-aminoacylation contribution remains debated, holding confidence at medium.

ClinVar Pathogenic Variants

View dHMN-5A ClinVar Variants

dHMN-5A OMIM Entry

dHMN-5A OMIM

GARS1 OMIM Entry

GARS1 OMIM

More Info

dHMN-5A Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Glycyl tRNA Synthetase Mutations in Charcot-Marie-Tooth Disease Type 2D and Distal Spinal Muscular Atrophy Type V

Authors

Antonellis, A., Ellsworth, R. E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S. Q., Jordanova, A., Kremensky, I., Christodoulou, K., Middleton, L. T., Sivakumar, K., Ionasescu, V., Funalot, B., Vance, J. M., Goldfarb, L. G., Fischbeck, K. H., & Green, E. D.

Publication Date
May 1, 2003

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Jean-Martin Charcot lecturing at the Salpêtrière while comparing anatomical illustrations of a cavovarus Charcot-Marie-Tooth (CMT) foot and a Charcot neuroarthropathy foot, highlighting two different conditions that share the Charcot name.


A Name That Does Too Much Work

Jean-Martin Charcot's name appears throughout medicine, but nowhere does it create more confusion than in the foot. Learn why the CMT foot and Charcot neuroarthropathy, also known as Charcot foot, share a name yet differ in how they develop, appear, and are managed.


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.